ScreenPoint Medical builds AI-powered software for the breast imaging continuum, with its flagship Transpara Breast AI Suite used to analyze 2D and 3D mammography exams and assist radiologists. The company reports Transpara Detection can boost cancer detection by 29% and has processed over 12 million mammograms across deployments in more than 30 countries. Founded in 2014 as a spin-off from Radboud University Medical Centre by Professors Nico Karssemeijer and Sir Michael Brady, ScreenPoint emphasizes clinical validation, including results from the MASAI randomized controlled trial published in The Lancet showing favorable outcomes versus standard double reading. Financially, it recently raised €11.9 million from existing investors Insight Partners and Siemens Healthineers and secured €1.7 million in research grants. The company plans to use the funding to accelerate product innovation, scale internationally, and pursue strategic initiatives to expand its role in breast cancer care.

Total raised

$44M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2026